European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-05-30

Molecular dissection of inflammatory pathways

Objectif

Inflammatory diseases are highly prevalent, often chronic diseases that cause diminished quality of life and are connected with major causes of death in Western societies. Despite their societal impact, their pathomechanism is incompletely understood, hindering development of novel therapeutic strategies. In particular, little is known about the intracellular signal transduction processes involved in the tissue destruction phase of aggressive autoimmune diseases such as rheumatoid arthritis. The present proposal aims to clarify this issue using in vivo and in vitro studies on genetically manipulated mice. During the proposed studies, mice deficient in various signal transduction molecules such as Syk, PLCg2, Gab2 and p190 RhoGAPs will be used to test their contribution to inflammatory responses. In vitro studies will test the activation of major effector cells of inflammation (neutrophils, macrophages and osteoclasts) while in vivo studies will utilize mouse models such as autoantibody- and cytokine-induced inflammatory arthritis or autoantibody-induced glomerulonephritis. Further studies will be performed to test the contribution of the above signaling molecules to disease pathogenesis in a lineage-restricted manner, using the Cre-lox approach. Finally, wild type and mutant versions of the signaling molecules tested will be retrovirally re-expressed into the relevant knockout hematopoietic stem cells in vivo to allow structure-function studies during in vivo inflammation. Two novel transgenic strains and a knock-in (floxed) mutant will also be generated during the course of the project. Using state-of-the-art approaches and techniques, this project will provide information at unprecedented molecular detail on signal transduction mechanisms involved in inflammatory diseases, and is expected to point to possible future targets of novel anti-inflammatory therapies.

Appel à propositions

ERC-2007-StG
Voir d’autres projets de cet appel

Régime de financement

ERC-SG - ERC Starting Grant

Institution d’accueil

SEMMELWEIS EGYETEM
Contribution de l’UE
€ 1 200 000,00
Adresse
ULLOI UTCA 26
1085 Budapest
Hongrie

Voir sur la carte

Région
Közép-Magyarország Budapest Budapest
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Irén Baumgartnerné Holló (Ms.)
Chercheur principal
Attila Mocsai (Dr.)
Liens
Coût total
Aucune donnée

Bénéficiaires (1)